Invivyd (NASDAQ:IVVD – Get Rating) had its price objective lowered by analysts at Morgan Stanley from $3.00 to $2.00 in a research report issued on Tuesday, Benzinga reports. The brokerage presently has an "underweight" rating on the stock. Morgan Stanley's target price would suggest a potential downside of 1.96% from the company's previous close.
Invivyd Stock Performance
Shares of NASDAQ IVVD opened at $2.04 on Tuesday. The company's 50-day moving average is $2.00. Invivyd has a 52-week low of $1.42 and a 52-week high of $12.11. The stock has a market cap of $222.32 million, a P/E ratio of -0.79 and a beta of -0.50.
Get Invivyd alerts:Invivyd (NASDAQ:IVVD – Get Rating) last issued its quarterly earnings data on Thursday, November 10th. The company reported ($0.42) earnings per share for the quarter, topping the consensus estimate of ($0.46) by $0.04. As a group, equities research analysts forecast that Invivyd will post -2.18 EPS for the current fiscal year.
About Invivyd
(Get Rating)Invivyd, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is adintrevimab, a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease.
Further Reading
- Get a free copy of the StockNews.com research report on Invivyd (IVVD)
- Intuit Is About To Make a Move, But Which Way?
- 3 Late January Earnings Plays With Pop Potential
- Low-Priced Stocks Still Paying Dividends
- Why is the Chipotle Stock Price Surging This Week?
- Is the Northrop Grumman Selloff an Opportunity?
Receive News & Ratings for Invivyd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invivyd and related companies with MarketBeat.com's FREE daily email newsletter.